Wei Wei

Wei Wei

Auto-generated profile, based on publicly available information

Wei Wei

Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JLJia-Run Lin
Jia-Run Lin
DHDuan-Duan Han
Duan-Duan Han
WWWei Wei
Wei Wei
QZQin Zeng
Qin Zeng
ZRZi-Xuan Rong
Zi-Xuan Rong
ZDZhong-Yi Dong
Zhong-Yi Dong
Aspirin has shown potential for cancer prevention, but a recent large randomized controlled trial found no evidence for a reduction in cancer risk. Given the anti-inflammatory effects of aspirin, systemic inflammatory diseases (SID), such as osteoporosis, cardiovascular diseases, and metabolic diseases, could potentially modify the aspirin-cancer link. To investigate the impact of aspirin in people with SIDs, we conducted an observational study on a prospective cohort of 478,615 UK Biobank participants. Individuals with at least one of the 41 SIDs displayed a higher cancer risk than those without SIDs. Regular aspirin use showed protective effects exclusively in patients with SID, contrasting an elevated risk among their non-SID counterparts. Nonetheless, aspirin use demonstrated preventative potential only for 9 of 21 SID-associated cancer subtypes. Cholesterol emerged as another key mediator linking SIDs to cancer risk. Notably, regular statin use displayed protective properties in patients with SID but not in their non-SID counterparts. Concurrent use of aspirin and statins exhibited a stronger protective association in patients with SID, covering 14 common cancer subtypes. In summary, patients with SIDs may represent a population particularly responsive to regular aspirin and statin use. Promoting either combined or individual use of these medications within the context of SIDs could offer a promising chemoprevention strategy. Significance: Individuals with systemic inflammatory diseases derive chemoprotective benefits from aspirin and statins, providing a precision cancer prevention approach to address the personal and public challenges posed by cancer.

1 January 2022 in Human & Experimental Toxicology
Verified
Journal Article
Open access
CLCheng Long
Cheng Long
LYLimei Yuan
Limei Yuan
WWWei Wei
Wei Wei
JLJingwen Li
Jingwen Li
The resistance of glioblastoma to chemotherapy remains a significant clinical problem. Targeting alternative pathways such as protein prenylation is known to be effective against many cancers. Fluvastatin is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl- CoA (HMG-CoA) reductase, thereby inhibits prenylation. We demonstrate that fluvastatin alone effectively inhibits proliferation and induces apoptosis in multiple human glioblastoma cell lines. The combination index analysis shows that fluvastatin acts synergistically with common chemotherapy drugs for glioblastoma: temozolomide and irinotecan. We further show that fluvastatin acts on glioblastoma through inhibiting prenylation-dependent Ras activation. The combination of fluvastatin and low dose temozolomide resulted in remarkable inhibition of glioblastoma tumor in mice throughout the whole treatment duration without causing toxicity. Such combinatorial effects provide the basis for utilizing these FDA-approved drugs as a potential clinical approach in overcoming resistance and improving glioblastoma treatment.

12 March 2026 in Communications Medicine
Verified
Journal Article
Open access
YRYingchen Ruan
Yingchen Ruan
MRMinjie Ruan
Minjie Ruan
ZFZhishen Fang
Zhishen Fang
ZSZhihua Sun
Zhihua Sun
KZKuimao Zhuang
Kuimao Zhuang
WWWei Wei
Wei Wei
The combination of immune checkpoint inhibitors (ICIs) with radiotherapy (RT) has improved survival in patients with advanced lung cancer, yet treatment-related pneumonitis (TRP) is highly toxic. Current limitations include the absence of robust risk stratification models for TRP and unclear safety criteria for ICI rechallenge, hindering the management of recurrent TRP (rTRP). In this multicenter retrospective study, we analyzed 262 lung cancer patients receiving radioimmunotherapy. The data included baseline demographics, immunotherapy regimens, and radiotherapy parameters. TRP was graded per CTCAE v5.0. Univariate and multivariate logistic regression identified predictors of TRP and rTRP severity. The incidence of TRP is 57.6% (151/262), with grade 1, 2, and ≥ 3 TRP occurring in 24.4%, 25.6%, and 7.6% of patients, respectively. The median time to TRP onset is 113 days (IQR, 73-155). Multivariate analysis reveals PD-1 inhibitors and ICI cycle number as predictors of G ≥ 1 TRP, whereas Dmean predicts all grades. Dose‒response modeling reveals Dmean thresholds for 50% TRP risk: 8.7 Gy (G ≥ 1), 15.3 Gy (G ≥ 2), and 23.4 Gy (G ≥ 3). Among the 53 patients receiving ICI rechallenge, 25.4% (13/53) developed rTRP. Rechallenge within 4 weeks significantly increases rTRP risk (OR, 0.061; 95% CI, 0.010-0.368; P = 0.002). Dmean serves as a continuous risk modifier for TRP severity, with Dmean > 15.3 Gy associated with grade ≥ 2 toxicity. An interval of ≥ 4 weeks after TRP is proposed as a safety window for ICI rechallenge, addressing critical gaps in radioimmunotherapy toxicity management.

4 June 2024
Verified
Other
Open access
JLJia-Run Lin
Jia-Run Lin
DHDuan-Duan Han
Duan-Duan Han
WWWei Wei
Wei Wei
QZQin Zeng
Qin Zeng
ZRZi-Xuan Rong
Zi-Xuan Rong
ZDZhong-Yi Dong
Zhong-Yi Dong
Aspirin has shown potential for cancer prevention, but a recent large randomized controlled trial found no evidence for a reduction in cancer risk. Given the anti-inflammatory effects of aspirin, systemic inflammatory diseases (SID), such as osteoporosis, cardiovascular diseases, and metabolic diseases, could potentially modify the aspirin-cancer link. To investigate the impact of aspirin in people with SIDs, we conducted an observational study on a prospective cohort of 478,615 UK Biobank participants. Individuals with at least one of the 41 SIDs displayed a higher cancer risk than those without SIDs. Regular aspirin use showed protective effects exclusively in patients with SID, contrasting an elevated risk among their non-SID counterparts. Nonetheless, aspirin use demonstrated preventative potential only for 9 of 21 SID-associated cancer subtypes. Cholesterol emerged as another key mediator linking SIDs to cancer risk. Notably, regular statin use displayed protective properties in patients with SID but not in their non-SID counterparts. Concurrent use of aspirin and statins exhibited a stronger protective association in patients with SID, covering 14 common cancer subtypes. In summary, patients with SIDs may represent a population particularly responsive to regular aspirin and statin use. Promoting either combined or individual use of these medications within the context of SIDs could offer a promising chemoprevention strategy.Significance:Individuals with systemic inflammatory diseases derive chemoprotective benefits from aspirin and statins, providing a precision cancer prevention approach to address the personal and public challenges posed by cancer.

4 June 2024
Verified
Other
Open access
JLJia-Run Lin
Jia-Run Lin
DHDuan-Duan Han
Duan-Duan Han
WWWei Wei
Wei Wei
QZQin Zeng
Qin Zeng
ZRZi-Xuan Rong
Zi-Xuan Rong
ZDZhong-Yi Dong
Zhong-Yi Dong
Supplementary Fig. S1-13,Supplementary Table S1-15

4 June 2024
Verified
Other
Open access
JLJia-Run Lin
Jia-Run Lin
DHDuan-Duan Han
Duan-Duan Han
WWWei Wei
Wei Wei
QZQin Zeng
Qin Zeng
ZRZi-Xuan Rong
Zi-Xuan Rong
ZDZhong-Yi Dong
Zhong-Yi Dong
Aspirin has shown potential for cancer prevention, but a recent large randomized controlled trial found no evidence for a reduction in cancer risk. Given the anti-inflammatory effects of aspirin, systemic inflammatory diseases (SID), such as osteoporosis, cardiovascular diseases, and metabolic diseases, could potentially modify the aspirin-cancer link. To investigate the impact of aspirin in people with SIDs, we conducted an observational study on a prospective cohort of 478,615 UK Biobank participants. Individuals with at least one of the 41 SIDs displayed a higher cancer risk than those without SIDs. Regular aspirin use showed protective effects exclusively in patients with SID, contrasting an elevated risk among their non-SID counterparts. Nonetheless, aspirin use demonstrated preventative potential only for 9 of 21 SID-associated cancer subtypes. Cholesterol emerged as another key mediator linking SIDs to cancer risk. Notably, regular statin use displayed protective properties in patients with SID but not in their non-SID counterparts. Concurrent use of aspirin and statins exhibited a stronger protective association in patients with SID, covering 14 common cancer subtypes. In summary, patients with SIDs may represent a population particularly responsive to regular aspirin and statin use. Promoting either combined or individual use of these medications within the context of SIDs could offer a promising chemoprevention strategy.Significance:Individuals with systemic inflammatory diseases derive chemoprotective benefits from aspirin and statins, providing a precision cancer prevention approach to address the personal and public challenges posed by cancer.